Korro Bio (KRRO) Cash from Financing Activities (2018 - 2026)
Korro Bio's (KRRO) quarterly Cash from Financing Activities came in at $88.2 million in Q1 2026, up 51186.05% YoY from N/an in Q1 2025, and up 23113.68% on a QoQ basis from $380000.0 in Q4 2025.
Korro Bio (KRRO) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Cash from Financing Activities data on file, last reported at $88.2 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 51186.05% year-over-year to $88.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.7 million (up 27.87% YoY) and the FY2025 annual result came in at $685000.0, down 99.01% from the prior year.
- Cash from Financing Activities rose to $88.2 million in Q1 2026, from $380000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $144.6 million in Q4 2023 to a low of -$2.2 million in Q3 2023.
- A 5-year average of $21.6 million and a median of $186000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 4014.29% — and 2024, when it soared 187755.56%.
- Tracing KRRO's Cash from Financing Activities over 5 years: stood at -$238000.0 in 2022, then jumped by 60851.26% to $144.6 million in 2023, then sank by 99.36% to $932000.0 in 2024, then sank by 59.23% to $380000.0 in 2025, then soared by 23113.68% to $88.2 million in 2026.
- The last three Cash from Financing Activities figures came in at $88.2 million (Q1 2026), $380000.0 (Q4 2025), and $128000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | -2.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.92 Mn |
| Jun 30, 2026 | -2.92 Mn |
| Mar 31, 2026 | 88.21 Mn |
| Mar 31, 2026 | 88.21 Mn |
| Dec 31, 2025 | 380,000.00 |
| Dec 31, 2025 | 380,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Jun 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 5,000.00 |
| Mar 31, 2025 | 172,000.00 |
| Mar 31, 2025 | 172,000.00 |
| Dec 31, 2024 | 932,000.00 |
| Dec 31, 2024 | 932,000.00 |
| Sep 30, 2024 | 728,000.00 |
| Sep 30, 2024 | 728,000.00 |
| Jun 30, 2024 | 67.56 Mn |
| Jun 30, 2024 | 67.56 Mn |
| Mar 31, 2024 | 139,000.00 |
| Mar 31, 2024 | 139,000.00 |